Search
Research
Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapyPeanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities. Allergen oral immunotherapy (OIT) is a promising approach, which is effective at inducing desensitisation; however, OIT has a limited ability to induce sustained unresponsiveness (SU).
Research
Epigenetic modifications: Mechanisms of disease and biomarkers of food allergyThe rise in IgE-mediated food allergy in recent times is the likely result of gene-environment interactions mediated via epigenetic pathways.
Research
Prevention and Natural History of Food AllergyThe rise in food allergy is more rapid than genetic deviation would allow and the current consensus is that environmental factors integrally linked to the...
News & Events
Back to school anxiety: How to help your child transition into the new school yearAs we count down to the end of the long summer holidays, it’s natural for children to feel anxious about what the new school year will bring.
News & Events
Cow’s milk protein allergies on the rise in our kidsUp to three out of every 100 babies develop cow's milk protein allergy (CMPA) in their first year of life – and this number appears to be on the rise
Research
Identifying gene network patterns and associated cellular immune responses in children with or without nut allergyAlthough evidence suggests that the immune system plays a key role in the pathophysiology of nut allergy, the precise immunological mechanisms of nut allergy have not been systematically investigated. The aim of the present study was to identify gene network patterns and associated cellular immune responses in children with or without nut allergy.
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.
News & Events
ORIGINS reaches key milestoneORIGINS, a collaboration between The Kids and the Joondalup Health Campus, has achieved a major milestone – recruiting its 1000th family.
News & Events
The Kids Research Institute Australia researchers share in TPCHRF fundingEight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).
News & Events
WATCH: Professor Susan Prescott's allergy adviceAllergy specialist Professor Susan Prescott gives her tips on how you can help prevent your child from developing a food allergy.